ANIX Anixa Biosciences Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 715446 · Fiscal year ends 10/31
Financial factors as of 2026-07-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY6.6%
TTM EPS YoY5.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-66.8%
ROA-63.4%
ROIC (approx.)-61.6%
Asset turnover—
Leverage & solvency
Liabilities / assets12.4%
Debt / equity0.00x
Current ratio8.54x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.71x
Accruals ratio-18.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-10-31 | FY20242024-10-31 | FY20232023-10-31 | FY20222022-10-31 | FY20222021-10-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $210,000 | $210,000 | — | $512,000 |
| R&D expense | $5.07M | $6.40M | $4.77M | $6.70M | $6.19M |
| SG&A expense | $6.63M | $7.43M | $6.29M | $7.17M | $7.07M |
| Operating income | -$11.70M | -$13.83M | -$11.01M | -$13.88M | -$13.14M |
| Net income | -$10.93M | -$12.55M | -$9.81M | -$13.60M | -$12.95M |
| EPS (basic) | -0.34 | -0.39 | -0.32 | 0.45 | -0.45 |
| EPS (diluted) | -0.34 | -0.39 | -0.32 | 0.45 | -0.45 |
| Weighted avg. shares (diluted) | 32,454 | 31,898 | 30,980 | 30,374 | 28.58M |
| Balance sheet | |||||
| Cash & equivalents | $1.24M | $1.27M | $915,000 | $12.36M | $29.13M |
| Short-term investments | $13.93M | $18.65M | $22.93M | $17.33M | $6.60M |
| Receivables | — | $173,000 | $270,000 | $46,000 | — |
| Current assets | $15.89M | $21.36M | $25.36M | $30.20M | $36.00M |
| Total assets | $16.08M | $21.59M | $25.52M | $30.41M | $36.26M |
| Current liabilities | $1.97M | $2.50M | $2.03M | $2.04M | $1.27M |
| Total liabilities | $2.13M | $2.70M | $2.15M | $2.21M | $1.49M |
| Shareholders' equity | $15.16M | $20.00M | $24.34M | $29.05M | $35.44M |
| Shares outstanding | 33.01M | 32.20M | 31.15M | 30.91M | 30.05M |
| Cash flow statement | |||||
| Operating cash flow | -$7.17M | -$7.33M | -$6.21M | -$6.49M | -$4.94M |
| Investing cash flow | $4.87M | $4.28M | -$5.60M | -$10.73M | -$3.92M |
| Financing cash flow | $2.28M | $3.42M | $366,000 | $452,000 | $31.57M |
| Stock-based compensation | $3.68M | $4.42M | $4.42M | $6.00M | $7.50M |
| Share buybacks | — | $6,000 | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.